Skip to main
ADCT
ADCT logo

ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics (ADCT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 20%
Sell 10%
Strong Sell 0%

Bulls say

ADC Therapeutics SA, a biotechnology company focused on developing antibody-drug conjugates for oncology treatments, is poised for significant revenue growth driven by its marketed product ZYNLONTA, which is currently experiencing annual sales of approximately $70 million in its approved indication. The company's conservative modeling indicates that the third-line treatment opportunity could expand, potentially increasing revenues by about $170 million and raising peak revenue estimates for ZYNLONTA to $629.1 million by 2032, significantly up from previous estimates. With the anticipated expansion of ZYNLONTA into second-line treatment and strong activity indicators in emerging markets, ADC Therapeutics is positioned for notable growth in the coming years, reflecting positively on its financial prospects.

Bears say

ADC Therapeutics faces significant challenges that contribute to a negative outlook on its stock performance. The company's reliance on third-party contract manufacturing organizations (CMOs) poses a risk of operational bottlenecks that could delay clinical trials and commercialization efforts, affecting its ability to generate revenue. Additionally, the potential for unfavorable clinical trial data related to its various product candidates and ongoing safety concerns could jeopardize the development pipeline, further complicating the pathway to achieving profitability and cash flow generation.

ADC Therapeutics (ADCT) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 20% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ADC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ADC Therapeutics (ADCT) Forecast

Analysts have given ADC Therapeutics (ADCT) a Buy based on their latest research and market trends.

According to 10 analysts, ADC Therapeutics (ADCT) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ADC Therapeutics (ADCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.